CLEMENTIA PHARM (NASDAQ:CMTA) – Stock analysts at Wedbush issued their Q3 2017 earnings per share (EPS) estimates for CLEMENTIA PHARM in a note issued to investors on Monday. Wedbush analyst D. Nierengarten forecasts that the company will post earnings of ($0.30) per share for the quarter. Wedbush has a “Outperform” rating and a $26.00 price target on the stock. Wedbush also issued estimates for CLEMENTIA PHARM’s Q4 2017 earnings at ($0.31) EPS, FY2018 earnings at ($1.48) EPS, FY2019 earnings at ($1.55) EPS, FY2020 earnings at ($1.62) EPS and FY2021 earnings at ($1.74) EPS.

A number of other brokerages have also issued reports on CMTA. Leerink Swann initiated coverage on shares of CLEMENTIA PHARM in a research note on Monday. They set an “outperform” rating and a $23.00 price target on the stock. BTIG Research initiated coverage on shares of CLEMENTIA PHARM in a research note on Thursday. They set a “buy” rating and a $32.00 price target on the stock. Finally, Morgan Stanley initiated coverage on shares of CLEMENTIA PHARM in a research note on Monday. They set an “overweight” rating and a $27.00 price target on the stock.

ILLEGAL ACTIVITY NOTICE: “CLEMENTIA PHARM (CMTA) to Post Q3 2017 Earnings of ($0.30) Per Share, Wedbush Forecasts” was first posted by Watch List News and is the property of of Watch List News. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://www.watchlistnews.com/clementia-pharm-cmta-to-post-q3-2017-earnings-of-0-30-per-share-wedbush-forecasts/1535186.html.

Shares of CLEMENTIA PHARM (CMTA) opened at 16.33 on Wednesday. The stock’s market cap is $498.51 million. The stock’s 50 day moving average is $16.04 and its 200 day moving average is $15.21. CLEMENTIA PHARM has a 52-week low of $15.05 and a 52-week high of $18.95.

CLEMENTIA PHARM Company Profile

Clementia Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. Its lead product candidate, palovarotene, is an oral small molecule that binds and activates retinoic acid receptor gamma (an RARg agonist), and has activity in preventing abnormal new bone formation as well as scar tissue formation (or fibrosis) in a variety of tissues in animal models.

Receive News & Ratings for CLEMENTIA PHARM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CLEMENTIA PHARM and related companies with Analyst Ratings Network's FREE daily email newsletter.